Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
The machine learning-powered RADR® platform identifies genomically distinct cancer subtypes, and patient groups, that can respond to specific drugs that Lantern and its partners are developingThe growing A.I. platform will be pivotal in uncovering combination therapies using Lantern’s portfolio of compounds together with both already marketed and approved therapeutics and, late-stage compounds in developmentDALLAS, June 29, 2020 (GLOBE NEWSWIRE) — Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and Rescue).RADR® leverages genomic, transcriptomic, clinical and drug sensitivity data points across more than 145 drug-tumor interactions to predict the potential response cancer patients will have to potential drugs, therefore enabling a more personalized approach to therapy that is aimed at better outcomes. Lantern is establishing collaborations and partnerships to expand the functionality of RADR®, including algorithms that can operate 200 to 300 percent faster than its existing algorithms, enabling the company to develop robust gene signatures that can be used to guide patient enrollment in trials and as a companion diagnostic (CDx). During the most recent data enrichment campaign, Lantern focused on significantly increasing the depth and amount of data for: non-small cell lung cancer, ovarian cancer, glioblastoma, and gliomas. Reaching this milestone of over 450 million curated data points for oncology drug development will bring greater precision and speed in helping Lantern with its objective of personalizing oncology therapy with reduced risk and cost. “Our approach in leveraging machine learning to develop biologically relevant, multi-gene signatures in days or weeks allows our team to more efficiently review and test novel insights about the complex mechanisms that can drive patient response to a drug,” said Panna Sharma, CEO of Lantern Pharma.As a pioneer in the application of machine learning to oncology-focused drug development and clinical trial design, Lantern has published gene signatures derived from RADR® as posters and presentations at both ASCO and AACR. Lantern’s pipeline of compounds includes one candidate in an active Phase 2 clinical trial for metastatic, hormone-refractory prostate cancer using a genomic signature for patient selection; another candidate in preparation for a Phase 2 clinical trial in non-small cell lung cancer in a targeted patient population; and a third candidate in two preclinical programs for biomarker-defined solid tumors and glioblastoma.Mr. Sharma continued, “Because of the increasing availability of large-scale biomarker, genomic and patient data, and rapidly maturing technologies like artificial intelligence and machine learning, oncology is undergoing a monumental shift in the way cancer drugs are discovered, developed, studied, targeted, and commercialized. Lantern is at the forefront of this transformation. For Lantern, exceeding 450 million data points is a significant milestone in our work, and demonstrates our commitment to leveraging paradigm changing technologies that transform oncology drug development with the ultimate objective of cost-effectively personalizing treatment for patients.”Lantern Pharma is ahead of the initial platform development schedule, reaching 400 million data points by the end of 2020, which puts Lantern on track to reach over 1 billion data points earlier than expected. The developmental focus on increasing the number of data points, and improving the performance of the algorithms is expected to yield additional targeted indications for Lantern’s current pipeline of drugs, and also help to uncover additional compounds and therapies that can be in-licensed or acquired and subsequently developed in a more efficient manner that leverages the insights from Lantern’s data-driven, A.I.-enabled approach.The market opportunity for RADR® as a platform for the development of targeted oncology therapies is significant. The highly scalable RADR® platform can be leveraged in multiple real-world applications, in addition to drug development, including: identifying potential drug combinations, predicting synergies with immune-oncology agents, developing companion diagnostics (CDx) and evaluating compounds for therapeutic efficacy and optimal positioning. Lantern is a pioneer in the adoption and implementation of data-driven and machine-learning enabled processes for drug development. The intersection of A.I., machine learning and genomics is considered a rapidly growing trend as researchers and investors turn to big data approaches to transform the cost, risk and timeline of oncology drug development.“Lantern Pharma is using genomics, machine-learning and big data in an effort to develop potentially life-saving cancer drugs, and our ability to fulfill this mission with greater efficiency and speed will be enhanced by focusing on the overall strength and scale of our platform,” concluded Mr. Sharma.About Lantern Pharma
Lantern Pharma is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern’s focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, two in clinical stages and one in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at www.lanternpharma.com or follow the company on Twitter @lanternpharmaContact: Kyle Evans, Public Relations
Email: firstname.lastname@example.orgForward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this press release include, among other things, statements relating to: the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of any of our drug candidates; our strategic plans to expand the number of data points that our RADR® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify patient populations that would likely respond to a drug candidate; and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Additional information regarding the risk factors to which we are subject is provided in greater detail in our final prospectus for our initial public offering on June 10, 2020, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Datametrex Announces Another Sale of COVID-19 Test Kits for $850,000 to a Canadian Mining Company
TORONTO, July 06, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce a purchase order (the “PO”) of 20,000 COVID-19 test kits from a Canadian based mining company (the “Purchaser”) with operations worldwide. This PO is for one of their Latin American mine operations.
The total gross sales amount is approximately $850,000 CDN, excluding shipping and courier fees. The Company has secured all requested testing kits, swabs, tubes, and the PCR machines. All of the items will be delivered directly to the mining company at their operating site in Latin America in mid-July. The Company anticipates little or no up front costs associated with the sale of these kits.“Datametrex is assisting with the implementing of test kits as it is a fundamental response to the pandemic, and those mining companies that have been able to test more comprehensively have had greater success,” says Marshall Gunter, CEO of the Company. “The reasoning is simple: An individual who tests positive can be isolated until they recover, and their contacts may be traced and similarly tested and isolated, effectively reducing the rate of transmission.”Under the terms of the PO, Datametrex will provide the Purchaser with 20,000 units of the COVID-19 qPCR Detection Kits manufactured by 1drop Inc. (“1drop”), 20,000 Universal Transport Medium (UTM®), Sterile Swabs with 16x100mm and Skirted Tubes. The Company also sold two (2) Real-Time Polymerase Chain Reaction Detection System (“PCR”) machines along with software to ensure optimal assay performance of the samples.Some Latin American countries are seeing shocking unemployment figures as the pandemic has caused hunger to rise in the region. The fallout from the pandemic is being felt hardest in Latin America, and has seen an almost three-fold rise in the number of people requiring government assistance, and among urban communities in low and middle-income countries, which are being dragged into destitution by job losses, especially in the mining sector. Millions of people are out of work in Brazil, Chile and Colombia, which have all attempted to re-open sectors of their economies but were hit with fast-spreading infections.About 1drop Inc.1drop Inc. aims to provide a solution to manage health with a drop of fluid. It has the key technologies for becoming a global leading company in the field of smart health care. 1copy™ COVID-19 qPCR Multi Kit can reduce the risk of asymptomatic and latent infection of COVID-19 by a single virus level limit of detection. Additional information on 1drop Inc. is available at www.1drop.co.krAbout DatametrexDatametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.Additional information on Datametrex is available at www.datametrex.comFor further information, please contact:Marshall Gunter – CEO
Phone: (514) 295-2300
Email: email@example.comNeither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsThis news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Gained Traction over the Past Few Years due the Rising Need for Energy Efficient Solutions in the Residential Sectors: Global Smart Thermostats Market
Covina, CA, July 06, 2020 (GLOBE NEWSWIRE) —The global smart thermostats market accounted for US$ 1.5 billion in 2019 and is estimated to be US$ 12.5 billion by 2029 and is anticipated to register a CAGR of 23.5%The report “Global Smart Thermostats Market, By Component (Display, Motion Sensor, Humidity Sensor, Temperature Sensor, and Others), By Network Technology (Wired Technology and Wireless Technology (Wi-Fi, Z-Wave, Zigbee, and Bluetooth)), By Application (Residential, Commercial, Industrial, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Trends, Analysis and Forecast till 2029”.Key Highlights:Nest Labs, Inc. offers networking products. The Company designs and manufactures a sensor-driven, Wi-Fi enabled, learning, and programmable thermostat. Nest Labs operates in the United States.Emerson Electric Co. designs and manufactures electronic and electrical equipment, software, systems, and services. The Company offers its products for industrial, commercial, and consumer markets worldwide through its network power, process management, industrial automation, climate technologies, and commercial and residential solutions divisions.Request Sample PDF of this Business Intelligence Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4376Analyst View:Speedy adoption of smart infrastructure in commercial and residential infrastructureTechnological advancements and shift in population towards convenient methods to remotely control electronic and electrical appliances drives the demand of the smart infrastructure. A smart thermostat is a device that is fitted in a smart infrastructure to provide users remote access to ambience heating or temperature. This offers benefits of switching heating systems through internet connected devices. Additionally, smart thermostats can also be arranged as per the need of users, which brings energy efficiency by limiting human error and negligence at times, which aids in the growth of smart thermostat market growth worldwide.Penetration of IoT and AI based technologiesAdvancements in IoT and AI has modernized electronic systems and devices. Additionally, the adoption of artificial intelligence in thermostats has advanced programmable thermostats to smart ones. Smart thermostat provides self-learning abilities and learn the user behavior over time. Thereby, automatically regulating temperature of the atmosphere. Smart thermostats are designed for connection over Wi-Fi and further advancements in these smart devices provides access to them via voice control, which boosts smart thermostat market growth across the globe.Ask for a Discount on the Current Pricing @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/4376Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Smart Thermostats Market”, By Component (Display, Motion Sensor, Humidity Sensor, Temperature Sensor, and Others), By Network Technology (Wired Technology and Wireless Technology (Wi-Fi, Z-Wave, Zigbee, and Bluetooth)), By Application (Residential, Commercial, Industrial, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Trends, Analysis and Forecast till 2029Key Market Insights from the report: The global smart thermostats market accounted for US$ 1.5 billion in 2019 and is estimated to be US$ 12.5 billion by 2029 and is anticipated to register a CAGR of 23.5%. The market report has been segmented on the basis of component, network technology, application, and region.By component, the global smart thermostats market is segmented into display, motion sensor, humidity sensor, temperature sensor, and others.By network technology, wireless technology is projected to offer great growth opportunity for the growth of global smart thermostat sensor market. Wireless network technology is further sub segmented into Wi-Fi, Z-Wave, Zigbee and Bluetooth.By application, commercial application segment involves healthcare, office building, and retail etc. Other Segment involves educational buildings such as school and colleges. Among all these application, residential applications are projected to grow expressively in the coming years due to the rising awareness about energy saving devices among consumers, advancement in home automation technology, and increasing demand of connected homes or smart homes.By region, The North American regional market is projected to lead the global industry owing to growing demand for managing energy consumption solutions and a wide distribution network of key manufacturers in the region. The rising average unit rate of power is inspiring household consumers, industries, and enterprises to implement smart energy solutions, which is one of the basic reasons for the market growth.To know the upcoming trends and insights prevalent in this market, click the link below:https://www.prophecymarketinsights.com/market_insight/Global-Smart-Thermostats-Market-4376Competitive Landscape:The prominent player operating in the global smart thermostats market includes Nest Labs, Inc., Emerson Electric Co., Ecobee Inc., Hive Home, Tado GmbH, Schneider Electric, Honeywell International Inc., Carrier Corporation, Siemens, Emerson Electric, and Vivint.The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.About Prophecy Market InsightsProphecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.Some Important Points Answered in this Market Report Are Given Below:Explains an overview of the product portfolio, including product development, planning, and positioningExplains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.Detailed analysis of the market revenue over the forecasted period.Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.Study on the segments that are anticipated to dominate the market.Study on the regional analysis that is expected to register the highest growth over the forecast periodKey Topics CoveredIntroductionStudy DeliverablesStudy AssumptionsScope of the StudyResearch MethodologyExecutive SummaryOpportunity Map AnalysisMarket at GlanceMarket Share (%) and BPS Analysis, by RegionCompetitive LandscapeHeat Map Analysis Market Presence and Specificity AnalysisInvestment AnalysisCompetitive AnalysisBROWSE RELATED REPORTS:Global DINRail Thermostats MarketGlobal Commercial Vehicle Thermostat MarketTo know more Contact Us:
Prophecy Market Insights Email- firstname.lastname@example.org
Patriot One Provides PATSCAN™ Platform Update
TORONTO, July 06, 2020 (GLOBE NEWSWIRE) — Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company”), offers the latest update on its PATSCAN™ Multi-Sensor Threat Detection Platform.
In May 2020, Patriot One’s Product Development Team responded to the Covid19 Pandemic as part of the Canadian Digital Technology Supercluster Covid19 Program. The Company secured up to $4.5 million (CAD) in co-investment funding under a two-stage program that includes development and deployment of (i) a thermal screening module that highlights persons presenting with elevated temperatures in real-time, using commodity-priced thermal cameras, (ii) additional computer modules that detect the presence or non-presence of medical and non-medical masks and face coverings, and the ability to highlight persons and problem areas where social distance requirements are not being maintained, and (iii) cross-location temperature monitoring to help the prediction of future outbreaks based on the overall trending and the combination of quantifiable indicators. Stage One comprises up to $2.25 million in investment to demonstrate the development of the modules over a four to six-month timeframe with on-site deployments with five or more co-development customers. In Stage Two, Patriot One will receive a second investment advance of up to $2.25 million over a six to eight-month timeframe to refine the Health & Safety Modules and redeploy with Stage One partners and customer(s). Patriot One’ s new Health & Safety modules are additional video object recognition solutions that are integrated into the PATSCAN™ Multi-Sensor Threat Detection Platform, which also includes weapon detection, disturbance and fight detection modules. The Health & Safety Modules use standard medium resolution thermal cameras, powered with the PATSCAN AI software to identify and analyze instances of elevated body temperature. Any anomalous detection outside a nominal body temperature range will result in an immediate alert, which will be instantly transmitted to onsite security for further action. In addition, Patriot One’s Xtract.ai division, in collaboration with Amazon Web Services, Vancouver General Hospital, University of British Columbia (“UBC”), and SapienML, helped radiologists identify the increased risk of the COVID19 virus. This project was led by Dr. Savvas Nicolaou and Dr. William Parker and supported by the UBC Community Health and Wellbeing Cloud Innovation Center (UBC-CIC) which has a mission to solve real-world challenges that materially benefit British Columbia and the world. Data captured from CT and X-ray scans from around the world, are being reviewed and annotated by 4 radiologists, who are labelling each image to segment them into three classes: background, normal lung, and Ground Glass Opacity (“GGO”). The percentage of lung volume affected by GGO is a leading indicator for COVID-19, and the development of an automated approach to assess this can greatly assist medical practitioners to quickly diagnose early onset of the virus. Beyond the PATSCAN VRS modules highlighted above, Patriot One’s product and engineering teams have been hard at work on the development of the PATSCAN™ Multi-Sensor Gateway, which combines multiple sensors with select proprietary detection technologies into one gateway system. As shared previously, by combining multiple sensors with the PATSCAN Artificial Intelligence neural network system (developed by the XTRACT.ai team), the Gateway’s overall performance level is dramatically enhanced and shows improved detection of personal concealed weapons.. The Patriot One product and engineering teams have been working side-by-side on the development and testing of the integrated Gateway solution. The result is a leading-edge, touchless detection technology that will save lives and modern society’s way of life. The PATSCAN™ Multi-Sensor Gateway will help protect on-site security, staff and visitors against weapons and other physical threats at building and venue entrances, as well as help identify potential viral threats with the addition of the thermal video recognition module. The PATSCAN™ Multi-Sensor Gateway (MSG 1.0) for Fastlane threat detection is planned for release to the North American market in August 2020 with several Gateway trial installations starting as early July 2020. In other news, Patriot One announces it has engaged Native Ads Inc. (“Native Ads”) to execute a comprehensive digital media marketing campaign for the Company. This programmatic digital advertising campaign will run for 12 weeks for a total spend of US$120,000, including content creation, web development, media buying and distribution, advertising creative development, campaign reporting and optimization.Respectfully“Martin Cronin”Martin Cronin, CEOAbout Patriot One
Patriot Ones’ mission is to deliver innovative threat detection and counter-terrorism solutions for safer communities. Our PATSCAN™ Multi-Sensor Covert Threat Detection Platform provides a network of advanced sensor technologies with powerful next generation AI/machine learning software. The network can be covertly deployed from far perimeter to interiors across multiple weapons-restricted facilities. The PATSCAN™ platform identifies and reports threats wherever required; car park, building approach, employee & public entryways and inside the facilities. Each solution in the platform identifies weapons, related threats or disturbances, or potential health and safety threats for immediate security response. Our motto Deter, Detect and Defend is based on the belief that widespread use of the PATSCAN™ platform will act as an effective deterrent to diminish the epidemic of active threats around the globe. For more information, visit: www.patriot1tech.com or follow us on Twitter and Facebook.About Native Ads
Native Ads is a full-service ad agency and operator of a programmatic ad exchange. Neither Native Ads, nor any of its directors and officers, own any securities of the Company.For further information, please contact:Patriot One Inquiries
John Martin, Patriot One
+1 (888) 728-1332
email@example.com Media Contacts:
Scott Ledingham, Patriot One
firstname.lastname@example.orgCAUTIONARY DISCLAIMER STATEMENT:
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to system sales, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects”,” believes”, and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include counterparty default and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable law.Neither the Toronto Stock Exchange (TSX) nor its Regulation Services Provider (as that term is defined in policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
Latest News1 year ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence1 year ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence1 year ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence1 year ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence1 year ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence1 year ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence1 year ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Artificial Intelligence3 months ago
Special Report: Coronavirus and the Housing Industry